New pill aims to plug protein leak in kidney patients
NCT ID NCT07614477
First seen May 30, 2026 · Last updated Jun 23, 2026 · Updated 4 times
Summary
This study tests an experimental drug called EVER001 in 45 adults with three types of kidney disease: FSGS, minimal change disease, and IgA nephropathy. Participants take the drug twice daily for a year to see if it reduces protein in the urine and is safe. The drug works on immune pathways without directly affecting T cells or depleting B cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
RECRUITINGBeijing, Beijing Municipality, 100730, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University General Hospital
RECRUITINGTianjin, Hebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EVER001
What this could lead to
If successful, this could point toward a new oral treatment option for certain kidney diseases that cause protein leakage.
What could go wrong
This is an early-phase trial with only 45 participants, so results may not apply broadly. The drug may not improve kidney function or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.